Clicky

Evaxion Biotech A/S(EVAX)

Description: Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Artificial Intelligence Surgery Immunotherapy Cancer Immunotherapy Vaccination Non Small Cell Lung Cancer Genomics Immunotherapies Melanoma Medical Genetics Bladder Cancer Viral Disease Cancer Vaccine Bacterial Disease Treatment Of Various Cancers Hernia Viral Infections S. Aureus

Home Page: www.evaxion-biotech.com

EVAX Technical Analysis

Dr. Neergaards Vej
Horsholm, 2970
Denmark
Phone: 45 53 53 18 50


Officers

Name Title
Dr. Niels Iversen Moeller M.D. Co-Founder, VP of Bus. & Director
Mr. Andreas Holm Mattsson Co-Founder and Chief AI & Culture Officer
Dr. Birgitte Rono Ph.D. Chief Scientific Officer
Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D. Chief Medical Officer
Dr. Per Norlen Chief Exec. Officer
Mr. Bo Lokke Karmark Chief Financial Officer
Mr. Jesper Nyegaard Nissen Chief Operating Officer
Dr. Jürgen Langhärig EMBA, Ph.D. Head of Bus. Devel. & Member of Advisory Board

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.8052
Price-to-Sales TTM: 0
IPO Date: 2021-02-05
Fiscal Year End: December
Full Time Employees: 70
Back to stocks